Abstract
Patients with Down syndrome (DS) have a unique genetic and clinical profile that may increase the risk of cancer. A literature search on PubMed, Scopus, Web of Science, and the Cochrane databases was conducted, focusing on studies to investigate the prevalence of solid and hematologic tumors in DS. Fifteen studies were included, encompassing 62,121 individuals with Down syndrome (DS). The overall prevalence of cancer in DS was 2.02% (95% CI: 1.63% to 2.50%). The analysis of hematological tumors revealed a prevalence of 1.18% (95% CI: 0.86% - 1.62%) for leukemia, 0.86% (95% CI: 0.73% - 1.01%) for acute lymphoblastic leukemia, and 0.51% (95% CI: 0.29% - 0.90%) for acute myeloid leukemia. Among solid tumors, testicular cancer had the highest prevalence, at 0.22% (95% CI: 0.12% - 0.43%). Our results highlight the need for targeted screening strategies, prevention strategies and treatment protocols among those with Down syndrome.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
